“Whether and How the U.S. Government Should Exercise Its Compulsory Licensing Authority Under 28 U.S.C. § 1498 and the Bayh-Dole Act”

  • Intellectual Property and Antitrust
New York University Journal of Intellectual Property and Entertainment Law
2021

“Anticommons, Transaction Costs, and Patent Aggregators”

  • Intellectual Property and Antitrust
Research Handbook on the Economics of Intellectual Property Law
2019

“Cannabis for Medical Use: FDA and DEA Regulation in the Hall of Mirrors”

  • Health Law
Food and Drug Law Journal
2019

“A Functional Approach to Judicial Review of PTAB Rulings on Mixed Questions of Law and Fact”

  • Intellectual Property and Antitrust
Iowa Law Review
2019

“Opting Into Device Regulation in the Face of Uncertain Patentability”

  • Intellectual Property and Antitrust
  • Law and Technology
Marquette Intellectual Property Law Review
2019

“Intellectual Property and Public Health”

  • Intellectual Property and Antitrust
  • Health Law
Oxford Handbook of Intellectual Property Law
2018

“Promoting Healthcare Innovation on the Demand Side”

  • Intellectual Property and Antitrust
  • Law and Technology
Journal of Law and the Biosciences
2017

“Insurance for broad genomic tests in oncology”

  • Health Law
Science
2017

“Diagnostics Need Not Apply”

  • Intellectual Property and Antitrust
  • Law and Technology
Boston University Journal of Science & Technology Law
2015

“Patents and Regulatory Exclusivity in the USA”

Encyclopedia of Health Economics
2014

“Wisdom of the Ages or Dead-Hand Control? Patentable Subject Matter for Diagnostic Methods After In Re Bilski”

  • Intellectual Property and Antitrust
Case Western Reserve Journal of Law, Technology & the Internet
2012

“Data Secrecy in the Age of Regulatory Exclusivity”

  • Intellectual Property and Antitrust
The Law and Theory of Trade Secrecy: A Handbook of Contemporary Research
2011

“Patent Costs and Unlicensed Use of Patented Inventions”

  • Intellectual Property and Antitrust
University of Chicago Law Review
2011

“Costs, Norms, and Inertia: Avoiding an Anticommons for Proprietary Research Tools”

  • Intellectual Property and Antitrust
Working Within the Boundaries of Intellectual Property: Innovation Policy for the Knowledge Society
2010

“One Size Fits All, After Tailoring”

  • Intellectual Property and Antitrust
Science
2009

“Patents and the Progress of Science: Exclusive Rights and Experimental Use”

  • Intellectual Property and Antitrust
The Economics of Innovation Policy
2008

“Pharma’s Nonobvious Problem”

  • Intellectual Property and Antitrust
Lewis and Clark Law Review
2008

“Noncompliance, Nonenforcement, Nonproblem? Rethinking the Anticommons in Biomedical Research”

  • Intellectual Property and Antitrust
Houston Law Review
2008

“The Supreme Court and the Federal Circuit: Visitation and Custody of Patent Law”

  • Intellectual Property and Antitrust
Michigan Law Review First Impressions
2007

“The Role of the FDA in Innovation Policy”

  • Intellectual Property and Antitrust
Michigan Telecommunications and Technology Law Review
2007

“Harnessing and Sharing the Benefits of State-Sponsored Research: Intellectual Property Rights and Data Sharing in California’s Stem Cell Initiative”

  • Intellectual Property and Antitrust
Berkeley Technology Law Journal
2006

“BioTech. Patents: Looking Backward While Moving Forward”

  • Intellectual Property and Antitrust
Nature Biotechnology
2006

“The Story of Diamond v. Chakrabarty: Technological Change and the Subject Matter Boundaries of the Patent System”

  • Intellectual Property and Antitrust
Intellectual Property Stories
2006

“Patents and Data-Sharing in Public Science”

  • Intellectual Property and Antitrust
Industrial and Corporate Change
2006

“Learning the Value of Drugs - Is Rofecoxib a Regulatory Success Story?”

  • Health Law
New England Journal of Medicine
2005

“The Problem of New Uses”

  • Health Law
Yale Journal of Health Policy, Law, and Ethics
2005

“How Can You Patent Genes?”

  • Intellectual Property and Antitrust
Genetics: Science, Ethics and Public Policy: A Reader
2005

“Reexamining Drug Regulation from the Perspective of Innovation Policy”

  • Health Law
Journal of Institutional and Theoretical Economics
2004

“Proprietary Considerations”

  • Health Law
Handbook of Stem Cells
2004

“Obvious to Whom? Evaluating Inventions from the Perspective of PHOSITA”

  • Intellectual Property and Antitrust
Berkeley Technology Law Journal
2004

“Patenting Genome Research Tools and the Law”

  • Intellectual Property and Antitrust
Comptes rendus Biologies
2003

“Patent Swords and Shields”

  • Intellectual Property and Antitrust
Science
2003

“Reaching Through the Genome”

  • Intellectual Property and Antitrust
Perspectives on Properties of the Human Genome Project
2003

“Can Patents Deter Innovation? The Anticommons in Biomedical Research”

  • Intellectual Property and Antitrust
Rights and Resources
2003

“Patents, Product Exclusivity, and Information Dissemination: How Law Directs Biopharmaceutical Research and Development”

  • Intellectual Property and Antitrust
Fordham Law Review
2003

“Bayh-Dole Reform and the Progress of Biomedicine”

  • Intellectual Property and Antitrust
Law and Contemporary Problems
2003

“Bayh-Dole Reform and the Progress of Biomedicine”

  • Intellectual Property and Antitrust
American Scientist
2003

“Patents on DNA Sequences: Molecules and Information”

  • Intellectual Property and Antitrust
The Commodification of Information
2002

“The Role of Patents in Exploiting the Genome”

  • Intellectual Property and Antitrust
The Genomic Revolution: Unveiling the Unity of Life
2002

“How Can You Patent Genes?”

  • Intellectual Property and Antitrust
Who Owns Life?
2002

Introduction to Genentech Legal Counsel and Vice President, 1976-1988, and Entrepreneur

Genentech Legal Counsel and Vice President, 1976-1988, and Entrepreneur
2002

“How Can You Patent Genes?”

  • Intellectual Property and Antitrust
American Journal of Bioethics
2002

“Public vs. Proprietary Science: A Fruitful Tension?”

  • Intellectual Property and Antitrust
Academic Medicine: Journal of the Association of American Medical Colleges
2002

“Can Patents Deter Innovation? The Anticommons in Biomedical Research”

  • Intellectual Property and Antitrust
Perspectives on Property Law
2002

“Why the Gene Patenting Controversy Persists”

  • Intellectual Property and Antitrust
Academic Medicine: Journal of the Association of American Medical Colleges
2002

“Public vs. Proprietary Science: A Fruitful Tension?”

  • Intellectual Property and Antitrust
Daedalus
2002

“The Shifting Functional Balance of Patents and Drug Regulation”

  • Intellectual Property and Antitrust
Health Affairs
2001

“Bargaining Over the Transfer of Proprietary Research Tools: Is This Market Failing or Emerging?”

  • Intellectual Property and Antitrust
Expanding the Boundaries of Intellectual Property: Innovation Policy for the Knowledge Society
2001

“Analyze This: A Law and Economics Agenda for the Patent System”

  • Intellectual Property and Antitrust
Vanderbilt Law Review
2000

“Ownership, Commercial Development, Transfer and Use of Publicly Funded Research Results: The United States Legal Regime”

  • Intellectual Property and Antitrust
The Role of Publicly Funded Research and Publicly Owned Technologies in the Transfer and Diffusion of Environmentally Sound Technologies
2000